DUBLIN, June 24, 2013 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/kzmqb4/pain_management) has announced the addition of the "Pain Management Treatment Markets" report to their offering.
Pain management drugs, or analgesics, can be categorized into three main modalities: acetaminophen, NSAIDs and opioids. Pain, meanwhile, can be categorized into four main modalities: acute, chronic, neuropathic and nociceptive.
The pain management market is currently valued at $52 billion.
Growing at a rate of 20%, the opioid segment will constitute a full 43% of the pain management market by 2018. Although the U.S. market will only increase modestly to $21.8 billion, it remains the largest market by far throughout the forecast period.
The "Pain Management Treatment Markets" report covers:
- CGRP antagonists
- CB2 agonists
- Sodium channel modulators
- Calcium channel modulators
- NMDA antagonists
- P2x receptors
- Trp channels
- TrpV1 blockers
- FAAH inhibitors
- Novel opioids
- Extended release formulations
- Transdermal formulations
The "Pain Management Treatment Markets" report examines companies manufacturing pain management equipment and supplies in the world. Companies covered include: Abbott, AcelRx, Acura, Afferent, Algiax, Arcion, Astellas, BioDelivery Sciences, Cara, Cephalon, Convergence, Cytogel, DURECT, Egalet, Eli Lilly, Endo, Grünenthal, Hospira, iMed, Johnson & Johnson, KemPharm, Mallinckrodt, NeurAxon, NeurogesX, Newron, Novartis, Nuvo, Pacira, Pain Therapeutics, Pfizer, Purdue, QRx, Relevare, Relmada, Spinifex, Xenon, Xenoport, Zalicus and Zogenix.
Detailed charts with sales forecasts and market-share data are included.
For more information visit http://www.researchandmarkets.com/research/kzmqb4/pain_management
SOURCE Research and Markets